Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Derrick Collier

Nurse Practitioner Cordele, GA Nurse Practitioner

NPI 1386167112 CMS profile 10772783

712 N 7Th St, Cordele, GA 31015

Open in the dashboard

General payments

$6,350

378 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Derrick Collier of Cordele, GA is reported in the CMS Open Payments database as having received $6,350 across 378 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,722 99
2024 General $1,194 63
2023 General $1,202 71
2022 General $1,026 61
2021 General $1,206 84

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Derrick Collier
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Derrick Collier were reported at $1,722. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Derrick Collier Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,206 $135 $40–$426 $132
2022 $1,026 $152 $48–$470 $149
2023 $1,202 $166 $54–$529 $160
2024 $1,194 $173 $55–$556 $164
2025 $1,722 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $986 52 payments
  2. Novo Nordisk Inc $871 49 payments
  3. AbbVie, Inc. $792 56 payments
  4. Amgen Inc. $652 48 payments
  5. GlaxoSmithKline, LLC. $544 37 payments
  6. Lilly USA, LLC $259 16 payments
  7. Novartis Pharmaceuticals Corporation $227 11 payments
  8. Janssen Biotech, Inc. $208 5 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $202 11 payments
  10. Idorsia Pharmaceuticals US Inc $137 9 payments
  11. Other $1,473 84 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,251 377 payments
  2. Education $99 1 payment
Products named General payments · program years 2021–2025
  1. Ozempic $581 32 payments
  2. RYBELSUS $540 30 payments
  3. TRELEGY ELLIPTA $513 35 payments
  4. FARXIGA $500 22 payments
  5. BREZTRI $427 19 payments
  6. VRAYLAR $420 26 payments
  7. UBRELVY $335 24 payments
  8. Otezla $327 28 payments
  9. AIRSUPRA $300 11 payments
  10. Repatha $292 19 payments
  11. Other $4,081 244 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 154 drugs

Part D claims

8,540

Median for Nurse Practitioner: 389

Drug cost

$816,904

Median for Nurse Practitioner: $21,885

Branded share of claims

22.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 80 $108,782
Jardiance Empagliflozin Brand 95 $91,728
Mounjaro Tirzepatide Brand 68 $75,664
Farxiga Dapagliflozin Propanediol Brand 75 $50,684
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 59 $44,602
Vraylar Cariprazine Hcl Brand 29 $41,432
Eliquis Apixaban Brand 47 $36,908
Linzess Linaclotide Brand 46 $35,367
Trulicity Dulaglutide Brand 20 $32,621
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 41 $26,798

The 10 drugs with the highest cost, of 154 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $115
$115 75 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $111
$111 59 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $99
$99 — —
TREMFYA
  • Janssen Biotech, Inc. $99
$99 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $58
  • Lilly USA, LLC $30
$87 95 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

378 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record